| Description |
xvii, 320 pages : illustrations ; 24 cm |
| Series |
RSC drug discovery ; 42 |
|
RSC drug discovery series ; 42
|
| Contents |
Contents note continued: 1.2.3.Sequence Retrieval and Alignment / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.4.Phylogenetic Analyses / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.5.Test for Recombination / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.6.Identifying Evolutionary Selection Pressures / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- |
|
Contents note continued: 1.2.7.Structural Analyses / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.8.Proteomics / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.9.Bioactivity Testing / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.3.Case Studies / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- |
|
Contents note continued: 1.3.1.Differential Evolution of Psammophis mossambicus SVMP Domains / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.3.2.Evolution of Vampire Bat Venom / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.3.3.Evolution of the Venom Apparatus and Peptide Toxin Characterisation in Terebrid and Turrid Marine Snails / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- |
|
Contents note continued: 1.4.Significance of the Combined Approach / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.4.1.Mutation of the Surface Chemistry / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.4.2.Alternative (Differential) Splicing / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.4.3.Post-Translational Modification / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- |
|
Contents note continued: 1.5.Concluding Remarks / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- Acknowledgements / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- References / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 2.1.Introduction / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.1.1.Venom Peptides / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.1.2.Disulfide Frameworks: Structural Skeletons Sustaining Bioactivity / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- |
|
Contents note continued: 10.4.2.ShK-F6CA, a Fluorophore-Conjugated ShK Analogue to Detect Kv1.3-Expressing Cells by Flow Cytometry / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.3.ShK-170, ShK-186, and ShK-192: ShK Analogues with Increased Selectivity and Stability / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.4.D-allo-ShK, an ShK Analogue Resistant to Endogenous Proteases / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.5.In vitro Biological Activity of ShK and Its Analogues / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.6.In vivo Biological Activity of ShK and Its Analogues / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.7.Pharmacokinetics of ShK and Its Analogues in Rats / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- |
|
Contents note continued: 10.4.8.Therapeutic Efficacy of ShK and Its Analogues in Treating Rat Models of Inflammatory Diseases / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.9.Toxicity Studies of ShK and Its Analogues in Mice and Rats / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.5.Into the Clinic / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.6.Further Developments / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.7.Conflict of Interest Statement / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- Acknowledgements / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- References / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 11.1.Introduction / Muharrem Akcan / David Craik -- 11.2.Synthesis / Muharrem Akcan / David Craik -- 11.3.Selected Examples / Muharrem Akcan / David Craik -- 11.3.1.Cyclic MII / Muharrem Akcan / David Craik -- |
|
Contents note continued: 11.3.2.Cyclic MrIA / Muharrem Akcan / David Craik -- 11.3.3.Cyclic ImI / Muharrem Akcan / David Craik -- 11.3.4.Cyclic Vc1.1 / Muharrem Akcan / David Craik -- 11.3.5.Cyclic AuIB / Muharrem Akcan / David Craik -- 11.3.6.Cyclic RgIA / Muharrem Akcan / David Craik -- 11.3.7.Cyclic Chlorotoxin / Muharrem Akcan / David Craik -- 11.3.8.Cyclic APETx2 / Muharrem Akcan / David Craik -- 11.4.Concluding Remarks / Muharrem Akcan / David Craik -- Acknowledgements / Muharrem Akcan / David Craik -- References / Muharrem Akcan / David Craik -- 12.1.Introduction / Oleg Werbitzky / Matthieu Giraud -- 12.2.Eptifibatide: Comparison of Two Synthesis Approaches-Liquid Phase versus Solid Phase Strategy / Oleg Werbitzky / Matthieu Giraud -- 12.3.Ziconotide: Example of a Stepwise Linear SPPS Strategy / Oleg Werbitzky / Matthieu Giraud -- 12.4.Industrial Synthesis of Exenatide: Example of a Convergent SPPS Strategy / Oleg Werbitzky / Matthieu Giraud -- |
|
Contents note continued: 12.5.Linaclotide: How to Cope with Disulfide Bridge Formation on a Large Scale? / Oleg Werbitzky / Matthieu Giraud -- 12.5.1.Random Strategy / Oleg Werbitzky / Matthieu Giraud -- 12.5.2.Regioselective and Semi-regioselective Strategies / Oleg Werbitzky / Matthieu Giraud -- 12.6.Conclusion / Oleg Werbitzky / Matthieu Giraud -- References / Oleg Werbitzky / Matthieu Giraud |
|
Contents note continued: 2.2.Diversity of Disulfide Scaffolds and Tertiary Structures / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.2.1.Overview of Framework Richness / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.2.2.Consensus Architectures of Venom Peptides / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.2.3.Taxon-Specific Disulfide Frameworks / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 2.3.Discussion / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- Acknowledgements / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- References / Vincent Lavergne / Paul F. Alewood / Mehdi Mobli / Glenn F. King -- 3.1.Introduction / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- |
|
Contents note continued: 3.2.Venom-Gland Transcriptomics / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.2.1.Sanger versus Next-Generation Sequencing / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.2.2.Bioinformatic Analysis of cDNA Libraries without a Reference Genome / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.3.Venom Proteomics / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- |
|
Contents note continued: 3.3.1.The Mass Spectrometer / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.3.2.Liquid Chromatography-Mass Spectrometry / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.3.3.MS Sequencing / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.3.4.Optimising Coverage / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- |
|
Contents note continued: 3.4.Bioinformatic Processing of Large-Scale Sequencing Data / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 3.5.Summary / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- References / Sebastien Dutertre / Eivind A.B. Undheim / Sandy S. Pineda / Ai-Hua Jin / Vincent Lavergne / Bryan G. Fry / Richard J. Lewis / Paul F. Alewood / Glenn F. King -- 4.1.Introduction / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.2.Isolation of Venom Components / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.3.Assay of Venom Components / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- |
|
Contents note continued: 4.4.Biological Systems: Tissues, Primary and Immortalised Cells / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.5.Bioassay / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.5.1.Skeletal Muscle Preparations / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.5.2.Smooth Muscle Preparations / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.5.3.Isolated Blood Vessels / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.5.4.Anaesthetised Whole Animals / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.6.Isolated Cell Studies of Venom Components / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.6.1.Electrophysiological Recording Techniques / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- |
|
Contents note continued: 4.6.2.High-Throughput Electrophysiology Assays / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 4.6.3.Biochemical Signalling / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- Acknowledgements / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- References / Irina Vetter / Peter McIntyre / David J. Adams / Wayne C. Hodgson -- 5.1.Introduction / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.2.Anti-Hypertensive Agents / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.2.1.Bradykinin-Potentiating Peptides / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.2.2.Natriuretic Peptides / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.2.3.L-Type Ca2+ Channel Blocker / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.3.Antiplatelet Agents / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- |
|
Contents note continued: 5.4.Disintegrins and Cancer Metastasis / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.Pro- and Anti-Coagulant Factors from Snake Venom / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.1.Snake Venom Thrombin-Like Enzymes (TLEs) / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.2.Factor Xa-Like Proteins / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.3.Factor Va-Like Proteins / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.4.Fibrin(Ogen)Olytic Metalloproteinases (FMPs) / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.5.Anti-Fibrinolytics / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.5.6.Direct Thrombin Inhibitors / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.6.Anti-Diabetic Agents / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- |
|
Contents note continued: 5.7.G-protein Coupled Receptor (GPCR) Antagonists/Agonists / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.8.Analgesics / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 5.9.Other Uses-Limitless Potential / Tse S. Kang / Ryan J.R. McCleary / R Manjunatha Kini -- 5.10.Conclusions / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- Acknowledgements / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- References / Ryan J.R. McCleary / R Manjunatha Kini / Tse S. Kang -- 6.1.Introduction / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.1.1.Biodiversity and Phylogeny of Venomous Molluscs / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.1.2.Overview / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- |
|
Contents note continued: 6.2.Physiology of Envenomation / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.2.1.Cabals and Constellations / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.2.2.Diversity of Cabals / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.3.Molecular Targets of Venom Peptide Families of Conoidea / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.3.1.A Conopeptide Family Targets a Corresponding Ion-Channel or Receptor Family / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- |
|
Contents note continued: 6.3.2.Individual Peptides of Conopeptide Families Can Be Used to Distinguish Between Closely Related Ion-Channel or Receptor Subtypes / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.3.3.Linking Biodiversity to Discovery: α-Conotoxins and nAChR Subtypes / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.3.4.Translational Applications of α-Conotoxins / Grzegorz Bulaj / Martin P. Horvath / J. Michael McIntosh / Baldomero M. Olivera / Russell W. Teichert -- 6.3.5.Molecular Determinants of Specificity / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- 6.4.Diversity of Conoidean Venom Components / Russell W. Teichert / Baldomero M. Olivera / Martin P. Horvath / Grzegorz Bulaj / J. Michael McIntosh -- |
|
Contents note continued: 6.4.1.Molecular Genetic Framework: Venom Peptide Superfamilies / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- 6.4.2.Generation of Peptide Diversity / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- 6.5.Conoidean Venom Peptides: Some Future Directions / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- 6.5.1.Kv-Channel Pharmacology: The Next Great Challenge / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- 6.5.2.Lessons Learned and Translating these to Biomedical Science / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- |
|
Contents note continued: 6.5.3.A New Paradigm for Discovery of Novel Pharmacological Agents / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- Acknowledgements / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- References / Russell W. Teichert / Baldomero M. Olivera / J. Michael McIntosh / Grzegorz Bulaj / Martin P. Horvath -- 7.1.Introduction / Lourival D. Possani / Ricardo C. Rodriguez de la Vega / Gerardo Corzo -- 7.2.Overview of Bioactive Peptides in Scorpion Venoms / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.3.Drug Candidates / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.3.1.Antimicrobial Peptides / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.3.2.Autoimmune Diseases / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- |
|
Contents note continued: 7.4.Pharmaceutical Tools / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.4.1.Tumor Labeling and Targeting / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.4.2.Drug Carriers / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.5."Toxin" Scaffolds as Platform for Drug Design / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 7.6.Future Prospects and Concluding Remarks / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- Acknowledgements / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- References / Ricardo C. Rodriguez de la Vega / Gerardo Corzo / Lourival D. Possani -- 8.1.Introduction / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- |
|
Contents note continued: 8.2.Non-ICK Spider-Venom Components / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.3.Spider-Venom ICK Peptides as Drug Leads / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.3.1.Spider-Venom Peptides for Treatment of Chronic Pain / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.3.2.Spider-Venom Peptides for Treatment of Stroke / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.3.3.Spider-Venom Peptides for Treatment of Autoimmune Diseases / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- |
|
Contents note continued: 8.3.4.Other Spider-Venom Peptides with Therapeutic Potential / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.4.Patents Detailing Therapeutic Applications of Spider-Venom Peptides / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.5.Future Challenges / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 8.6.Conclusions / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- Acknowledgements / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- References / Jennifer J. Smith / Carus Ho Yee Lau / Volker Herzig / Maria P. Ikonomopoulou / Lachlan D. Rash / Glenn F. King -- 9.1.Introduction / Richard J. Lewis -- |
|
Contents note continued: 9.2.Calcium Channels in Pain Pathways / Richard J. Lewis -- 9.3.Analgesic ω-Conotoxins / Richard J. Lewis -- 9.4.Analgesic χ-Conotoxins / Richard J. Lewis -- 9.5.Comparison of Direct and Indirect Inhibition of Cav2.2 / Richard J. Lewis -- Acknowledgements / Richard J. Lewis -- References / Richard J. Lewis -- 10.1.Introduction / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.2.The Toxin / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.3.The Target: Kv1.3 / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.3.1.How ShK Blocks K+ Channels / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.Transforming the Toxin into a Therapeutic / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- 10.4.1.ShK-Dap22, the First ShK Analogue with Increased Selectivity for Kv1.3 over Kv1.1 and Other K+ Channels / Raymond S. Norton / Michael W. Pennington / Christine Beeton -- |
|
Machine generated contents note: 1.1.The Fundamental Problems / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.The Solutions / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.1.Taxon Selection / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- 1.2.2.Transcriptomics / Bryan G. Fry / Ivan Koludarov / Timothy N. W. Jackson / Mande Holford / Yves Terrat / Nicholas R. Casewell / Eivind A.B. Undheim / Irina Vetter / Syed A. Ali / Dolyce H.W. Low / Kartik Sunagar -- |
| Summary |
This unique book will provide an up to date and comprehensive account of the potential of peptides and proteins from animal venoms as possible therapeutics. The pharmaceutical industry has become increasingly interested in biologics from animal venoms as a potential source for therapeutic agents in recent years, with a particularly emphasis on peptides. To date six drugs derived from venom peptides or proteins have been approved by the FDA, with nine further agents currently being investigated in clinical trials. In addition to these drugs in approved or advanced stages of development, many more peptides and proteins are being studied in varying stages of preclinical development. Topics covered include chemistry and structural biology of animal venoms, proteomic and transcriptomic approaches to drug discovery, bioassays, high-throughput screens and target identification, and reptile, scorpion, spider and cone snail venoms as a platform for drug development. Case studies are used to illustrate methods and successes and highlight issues surrounding administration and other important lessons that have been learnt from the development of approved therapeutics based on venoms |
| Notes |
Formerly CIP. Uk |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Also issued online |
| Subject |
Drug development.
|
|
Pharmaceutical biotechnology.
|
|
Venom -- Therapeutic use.
|
|
Venoms -- therapeutic use.
|
| Author |
King, Glen F., editor
|
| LC no. |
2014451070 |
| ISBN |
9781849736633 (print) |
|
(PDF) |
